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Abstract
The COVID-19 pandemic has magnified an already existing trend of people look-
ing for healthcare solutions online. One class of solutions are symptom checkers,
which have become very popular in the context of COVID-19. Traditional symp-
tom checkers, however, are based on manually curated expert systems that are
inflexible and hard to modify, especially in a quickly changing situation like the
one we are facing today. That is why all COVID-19 existing solutions are manual
symptom checkers that can only estimate the probability of this disease and can-
not contemplate alternative hypothesis or come up with a differential diagnosis.
While machine learning offers an alternative, the lack of reliable data does not
make it easy to apply to COVID-19 either.
In this paper we present an approach that combines the strengths of traditional AI
expert systems and novel deep learning models. In doing so we can leverage prior
knowledge as well as any amount of existing data to quickly derive models that
best adapt to the current state of the world and latest scientific knowledge. We use
the approach to train a COVID-19 aware differential diagnosis model that can be
used for medical decision support both for doctors or patients. We show that our
approach is able to accurately model new incoming data about COVID-19 while
still preserving accuracy on conditions that had been modeled in the past. While
our approach shows evident and clear advantages for an extreme situation like the
one we are currently facing, we also show that its flexibility generalizes beyond
this concrete, but very important, example.
1 Introduction
In a world where many people don’t have access to essential healthcare services, and doctors have an
average of 15 minutes per patient, it does not come as a surprise that a global pandemic like COVID-
19 would place unprecedented stress on the global healthcare system. In this situation many have
turned to telemedicine as a way to scale healthcareJudd E. Hollander and Brendan G. Carr [2020].
However, telemedicine on its own is just a different format for old workflows and processes. In
order to scale telemedicine itself we need to increase both efficiency and accuracy of the outcomes
by using AI and automation.
In fact, AI has been connected to medicine since the very beginning. Early AI approaches like ex-
pert systems have been used for decades as medical decision support tools. These expert systems are
designed by domain experts (i.e. doctors) who build knowledge bases that are then used to reason
about real-world situations. This approach is very similar to the more modern user-facing symptom
checkers that have been popularized in the internet age. Online symptom checkers are assessment
tools where users enter their symptoms and expect to get some guidance on their possible condi-
tion. These tools have even become more prevalent in the COVID-19 age, where many healthcare
providers have tried to automate a response to the important question of ”Do I have COVID-19?”.
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It is important to note that online COVID-19 symptom checkers are only able to give a response
to the likelihood of a person having COVID-19, but they cannot give a holistic assessment of the
patient. In other words, they cannot tell the patient that they are unlikely to have COVID-19, but
rather should worry about strep throat. This highlights one of the main shortcoming of expert sys-
tems: they are hard to scale and lack flexibility. Adding a new condition to a well-tuned expert
system requires re-tuning system by re-adjusting, mostly manually, all the existing probabilities. In
the early stages of the COVID-19 pandemic where knowledge about the disease evolved on a daily
basis, this methodology is not effective.
A more novel and very different approach to building diagnosis models is, of course, to use data and
machine learning. Indeed, the recent advent of access to digital resources such as electronic health
records holds promise as a major avenue for timely access to highly granular patient-level data.
Large data repositories with detailed medical information can be mined through machine learn-
ing (ML) techniques to automatically learn fine-grained diagnosis models. These machine-learned
models can capture patterns at different levels of granularity, and they can be easily extended and
updated, as new data becomes available. On the downside, directly incorporating prior medical
knowledge gathered through clinical research into machine learned models is difficult. Therefore,
these ML models will only be as good as the data on which they are trained. This becomes par-
ticularly limiting in a situation like the one we are facing with COVID-19 in which data is hardly
available and of limited quality.
In this paper we address the very timely and highly important question of whether we can quickly
learn a generalized diagnosis model when a new condition like COVID-19 appears, even when the
data around it is still questionable. In order to answer this question, we extend some previous work
combining expert systems and machine learning approaches Ravuri et al. [2018].
More concretely, the contributions of this work are the following:
1. We present a machine learning approach and method to quickly enhance an existing AI
diagnosis model to incorporate a novel disease like COVID-19
2. We show that the resulting model is accurate in including COVID-19 in the differential
diagnosis, without losing accuracy in diagnosing previously existing conditions
3. We show that the approach is easily extensible as new evidence or findings about the new
condition are surfaced.
2 Related work
Differential diagnosis as Inference: Early models for diagnosis were AI expert system models used
as medical decision support systems for physicians (c.f. Mycin (Buchanan and Shortliffe [1985]),
Internist-1 (Miller et al. [1982]), DXplain (Barnett et al. [1987]) and QMR (Rassinoux et al. [1996])).
The goal of these systems was to emulate physicians’ medical diagnostic ability to provide an ”inde-
pendent expert opinion” that could be leveraged by physicians when making a final decision. These
systems have two components: an expert-curated knowledge base and an inference engine that is
manually optimized. A fundamental limitation of these approaches and their probabilistic counter-
parts (c.f.Shawe and Cooper [1990], Morris [2001]) is the knowledge acquisition problem Gaines
[2013], Miller et al. [1986]: the knowledge base construction is time-consuming. Adding an extra
disease requires weeks of work from expert physicians who need to corroborate evidences from
multiple peer-reviewed publications and other sources. For rapidly evolving conditions such as the
COVID-19 pandemic, it may take several years before it becomes part of the expert system. Note
that not only scientific knowledge related to the specific disease needs to stabilize, but in order to
add it to the knowledge base, we need to be able to model it in the presence of other diseases (e.g.
how does the probability of someone having the flu given a high fever change given the possibility
of that patient also now having COVID-19).
Machine learned models Machine learning provides a viable scalable path to quickly learn (and
revise) models of differential diagnosis, as they depend on patient-level data available from sources
such as electronic health records. While the initial work in this space has been on learning diagnostic
codes (ICD) predictions using deep neural networks, either instantaneously or through time (c.f.
Miotto et al. [2016], Ling et al. [2017], Shickel et al. [2017], Rajkomar et al. [2018], Liang et al.
[2019] and references therein), more recently, Ravuri et al. [2018], Kannan et al. [2020], these
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approaches have been applied to directly modeling the task of coming up with a differential diagnosis
in a manner that is useful in patient-facing settings such as online symptom checkers. Ravuri et al.
Ravuri et al. [2018] also introduce the idea of using expert systems as a data prior which forms the
basis of our current work. We compare to that work in the next section.
3 Approach Overview
We are interested in learning a user-facing machine learned model for differential diagnosis that
can consider COVID-19 as a potential disease in its label space of diagnosis, and that such a model
can be applied in online symptom checkers. We learn this model (§ 4) by combining data from
two distinct sources. The first source is the AI medical expert system from which clinical cases are
simulated to capture all but COVID-19 diseases (§ 3.1). The second source is the data collected from
an online COVID assessment flow wherein flows that ended with low to medium risk are treated as
positive examples of COVID-19 (§ 3.2).
Novelty of the approach: The proposed model is trained with an objective that takes into account
the differential diagnosis of the clinical case, and not just a single disease. With our proposed
model, we combine the best of both worlds: a very focused COVID-19 assessment tool to capture
the changing guidelines and known medical evidence for COVID-19 (eg. incorporating anosmia
as a new finding), and the generality of a symptom checker that understands many other condi-
tions besides COVID-19. The duality of the approach allows the consideration of COVID-19 in a
differential diagnosis whenever appropriate while also modeling the probabilities of competing hy-
pothesis. This paper extends the work of Ravuri et al. [2018] in multiple directions. To the best of
our knowledge, this paper is the first in incorporating COVID-19 as part of the differential diagnosis
for an automated diagnosis assessment. Another difference to pre-existing work, that is particularly
relevant for COVID-19, is that in this work we combine the data from the expert system with a
snapshot of a dataset collected from an online COVID-19 assessment tool, as opposed to e.g. data
from EHRs. In a rapidly evolving situation like the one we face today, data from EHR is still noisy
and incomplete. Using data from a specific online assessment tool is a novel approach to not only
quickly generate data, but also to incrementally improve it over time as new information about the
condition is uncovered and added to the assessment. Finally, the model proposed in this paper di-
rectly operates on the findings/symptoms observed to be either positive or negative, while previous
work uses tokens in findings as input vocabulary.
3.1 Clinical case simulation
Simulator: We use simulation algorithm to create a large number of clinical vignettes from an ex-
tended version of the QMR knowledge base Miller and Masarie Jr [1990] to use as our dataset.
This knowledge base contains of 830 diseases, 2052 findings (covering symptoms, signs, and demo-
graphic variables), and their relationships. Relationships between finding-disease pairs are encoded
as evoking strength (ES) and term frequency (TF), with the former indicating the strength of associa-
tion between the constituent finding-disease pair and the latter representing frequency of the finding
in patients with the given disease.
The simulation algorithm [Parker and Miller, 1989, Ravuri et al., 2018] makes a closed world as-
sumption with the universe of diseases (denoted Y) and findings (F ) being those in the knowledge
base. Algorithm 1 outlines the algorithm. The simulator first samples a disease d ∈ Y and de-
mographic variables, and then samples findings in proportion to frequency for the chosen disease.
Each sampled finding is assigned to be present fposor absent fneg , based on frequency. If assigned
present, then findings that are impossible to co-occur are removed from consideration (e.g. a per-
son cannot have both productive and dry cough). The simulation for a case ends when we sampled
random (5-20) findings are recorded.
For our experiments, we limit to demographic variables and symptoms as these are the most likely
available findings when first diagnosing a patient in a telehealth setting. After simulating the find-
ings, there is still an uncertainty in the final diagnosis because of two main reasons: (1) The user
facing findings may not sufficiently narrow down on a single diagnosis, and/or (2) the randomness in
the number of findings chosen for the case may not be sufficient to arrive at a diagnosis. Therefore,
we use the inference algorithm of the expert system to obtain a differential diagnosis, along with
their scores. These scores are then normalized to represent probability distribution. We ignore cases
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for which the score distribution has high entropy. Fig. 2 provides example cases obtained using this
algorithm. The differential diagnoses in each of these cases are peaked around a small number of
diseases.
The resulting dataset consists of 65,000 distinct clinical cases with 437 diseases and 1418 findings.
Each disease is supported by at least 50 clinical cases.
Algorithm 1 Clinical case simulation algorithm
1: Input: Medical knowledge base of diseases (D) and findings (F) with relationships between
them encoded by FREQ(d,f), where FREQ(d,f) is transformed to represent p(f = 1|d); number
of cases T. Expert Inference engine ExpertInference that takes us input a set of findings and
provides the differential diagnosis.
2: Output: {f (t),ddx(t)}Tt=1 pairs. such that y ∈ D and f ⊂ F is the set of findings needed to
arrive at ddx. ddx is differential diagnosis consisting of K pairs of ( y ∈ D, s ∈ [0, 1] such that∑
sk = 1
3:
4: for t = 1 to T do
5: y ∼ Uniform(D∗) . Candidate disease label for this case
6: f (t) ← ∅
7: F ∗ = sort(F , FREQ(y, :)) . Findings sorted by frequency
8: for f ∈ Demographics(F) do . Demographic variables
9: if f ∈ F ∗and rand() > FREQ(f, y) then
10: f (t) ← f (t) ∪ {f}
11: F ∗ ← RemoveMutex(F ∗, f (t)) . Remove all findings that can not co-manifest with
f (t)
12: L = randint(5, |F ∗|) + |f (t)| . Sample number of findings in the case
13: F ∗ ← F \ Demographics(F)
14: while |f (t)| ≤ L do
15: F ∗ ← RemoveMutex(F ∗, f (t))
16: f∗ ← GetNext(F ∗) . Next finding to be visited
17: if rand() > FREQ(f, y(t)) then
18: f (t) ← f (t) ∪ {f∗}
19: F ∗ ← F ∗ \ {f∗}
20: ddx(t) ← ExpertInference(f (t))
3.2 Data from COVID assessments
The COVID-19 dataset used in our models was generated from a virtual diagnostic assessment that
guides users through a comprehensive set of clinical questions asked by physicians to determine
the likelihood of COVID-19 infection and associated complications from the disease (Figure 1).
Questions in the assessment were based on guidance provided by the United States Centers for
Disease Control and Prevention (CDC) at the time and elicited information regarding clinical factors
including:
• Demographic information
• Symptoms
• COVID-19 exposure risks
• Medical history
• Medications
Each clinical factor’s effect on the patient’s symptoms were used to determine the likelihood of
COVID-19 infection. For example, a younger user with a weakened immune system with a recent
exposure to the virus would likely have milder or no symptoms as compared to an older user with
lung disease with exposure seven days prior to undergoing the assessment. Based on the CDC guide-
4
Findings Differential Diagnosis
female
young adult (18 to 40 yrs)
few days (2-7 days)
cough
productive cough
malaise
fever
nose discharge
bacterial pneumonia (26.9)
influenza (23.4)
acute sinusitis (22.9)
male
middle age (41 to 70 yrs)
prolonged (1-4 weeks)
foot pain
heel pain
movement pain
walking pain
limping
plantar fasciitis (38.9)
stress fracture (31.5)
female
middle age (41 to 70 yrs)
chronic (> 4 weeks)
urinary urgency
change in bladder habits
nocturia
urinary frequency
female urethritis (32.9)
overactive bladder (26.9)
Table 1: Examples of clinical cases using simulation from expert system (§ 3.1). While the expert
systems provide raw scores, these are converted into probabilities through normalization.
Moderate COVID-19 risk
• male, middle age (41 to 70 yrs), nasal congestion, nose discharge, been in Japan in the
past 14 days prior to the onset of symptoms prolonged exposure to person with confirmed
COVID-19 case (but not close contact)
• female, middle age (41 to 70 yrs), lightheadedness, dyspnea, chest pain, dyspnea, exer-
tional, foreign travel history, hospital personnel, dyspnea at rest
Low COVID-19 risk
• female, middle age (41 to 70 yrs), cough, headache, hospital personnel, cigarette smoking,
nose discharge
• male, middle age (41 to 70 yrs), lightheadedness, cough , nasal congestion, sore throat,
headache, hospital personnel, nose discharge
Table 2: Examples of cases from COVID asessment flow.
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Figure 1: Example screenshots from COVID-19 assessment flow from which the data for our work
is derived. See § 3.2 for details
• been in China in the past 14 days prior to the onset of symptoms
• been in Europe in the past 14 days prior to the onset of symptoms
• been in Iran in the past 14 days prior to the onset of symptoms
• been in Japan in the past 14 days prior to the onset of symptoms
• dyspnea at rest
• hospital personnel
• exposure to coronavirus disease 2019 within the last 14 days from symptom onset
• healthcare contact with confirmed COVID-19 case not using any personal protective equipment
• household contact with confirmed COVID-19 case
• prolonged exposure to person with confirmed COVID-19 case (but not close contact)
• recent close contact with a person with symptomatic confirmed COVID-19 case
Table 3: Findings unique to COVID-19 assessment data
lines, exposure risks had a significant effect on the calculations in the early stages of the COVID-19
pandemic.
For our approach, we used two variants of data gathered by the assessment. In one variant, we
restricted to only finding that are also part of the expert system. This removed factors (Table 3) that
were more reflective of the timing of the guidelines at the time of data collection and less reflective of
inherent diagnostic criteria such as recent travel history and epidemiological data based on location
and living with an individual with known COVID-19 infection. In the second variant, we included
all the available findings.
4 Model
We are interested in building a machine learned model that takes findings as input, and outputs a
ranked list of possible conditions (a.k.a. differential diagnosis). We formulate this as a classification
task, and use the output scores from the model to rank the conditions in the differential diagnosis.
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Figure 2: Model Architecture used in learning to diagnose
Let F = {f1, · · · , fK} be the universe of all the findings that can be elicited from the patients.
Examples of findings include ‘eye pain’, ‘nausea’ and ‘fever’. Let Y = {1, ..., L} correspond to L
diagnoses that are of interest. Examples of diagnoses include ‘COVID-19’, ‘arthritis’ and ‘common
cold’.
A clinical case consists of (a) a set of findings xpos ∈ F that are observed in the patient; (b) a
disjoint set of findings xneg ∈ F that are explicitly observed to be not present in the patient; and (c)
the corresponding differential diagnoses ddx such that ddx = {yj ∈ Y, sj}j=Lj=1 , where sj (with∑
j sj = 1) is the probability of yj to be considered the true underlying diagnosis. We also assume
that demographic variables such as gender and age are also part of xpos. Clearly, xpos ∩ xneg = ∅.
While one may argue that all findings that are not present in the patient are therefore absent, in
reality, the doctors gather information that are pertinent to the observed findings so as to rule-out
possibly related diseases. In order to mimic this, we make the assumption that |xpos∪xneg| << |F|.
We assume access to a labeled data set of N clinical cases, D =
{(x(1)pos,x(1)neg,ddx(1)), · · · , (x(N)pos ,x(N)neg ,ddx(N)).
Soft Cross-entropy loss: The goal is to learn a function from g : X 7→ Y that minimizes empirical
risk:
min
g∈G
N∑
n=1
loss(ddx(n), g(x(n))) (1)
where loss measures the discrepancy between the true label distribution ddx(n) and the predicted
distribution g(x(n)). During evaluation we use 0/1 loss and during training, we use the surrogate
soft cross entropy loss between encoding of yn as a probability distribution and the output softmax
probability vector provided by the function g.
Loss: In a typical classification cross entropy loss, the target is a vector with one non-zero entry
corresponding to the ground truth label. However, often in clinical diagnosis setting, there is always
some amount of uncertainty in the final diagnosis. As an example, for a patient with “cough”, there
are many possible diseases to be considered with some diseases such as “common cold’ or ‘flu’
having a higher probability than diseases such as ‘pneumonia’. In order to capture this, the target
vector is a distribution over the plausible diagnoses, where the probability is based on the scores
associated with the differential diagnoses. In Mahajan et al. [2018], a similar construct was used
in the context of image classification but assumed a uniform distribution over the target labels, and
hence set the target to 1/k corresponding to the k ≥ 1 labels for the image.
We acknowledge that even though the loss function models the entire differential diagnosis, we
would ideally have a loss function that is cost-sensitive. For instance, misdiagnosing a disease that
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Approach top-1 top-3 top-5
Human-Doctors Evaluation Fraser et al. [2018] 72.1% 84.3 % -
AI expert system 66% 75% 86%
Razzaki et.al. Razzaki et al. [2018] - 46.6% 64.67%
Kannan et.al. Kannan et al. [2020] 50.67% (1.86) 75.11% (1.86) 82.22% (1.56)
Ours-BASE 67.6% (.023) 85.8% (.025) 92.9% (.009)
Ours-BASE-COVID 61.8% (.029) 84.4% (.027) 93.3% (.000)
Ours-BASE-COVID-FULL 65.5% (.012) 84.4% (.041) 93.3% (.000)
Table 4: Comparison of performance between different models.
Findings Findings in our feature space Label Ours-BASE Ours-BASE-COVID
30 y/o m
2 day HX of runny nose
sore throat
hot, sweaty
mild headache
cough with clear sputum
muscle aches
no fever or neck stiffness
male
young adult (18 to 40 yrs)
brief (6-48 hours)
nose discharge
sore throat
sweating increase
headache
productive cough
generalized myalgia
no fever
no neck stiffness
viral upper respiratory
viral upper respiratory (0.415)
influenza (0.298)
acute sinusitis (0.044)
streptococcal pharyngitis (0.028)
bacterial pneumonia (0.026)
viral upper respiratory (0.257)
influenza (0.218)
COVID-19 (0.181)
streptococcal pharyngitis (0.029)
opioid withdrawal (0.022)
18 y/o m
3 days severe headache
fever
photophobia,
neck stiffness
male
young adult (18 to 40 yrs)
severe headache
fever
photophobia
neck stiffness
meningitis
(bacterial) meningitis (0.869)
West Nile fever (0.102)
Rocky Mountain spotted fever (0.009)
influenza (0.005)
relapsing fever (0.002)
(bacterial) meningitis (0.771)
West Nile fever (0.200)
Rocky Mountain spotted fever (0.009)
influenza (0.005)
epidemic myalgic encephalomyelitis (0.002)
Table 5: Sample model predictions for examples from Semigran. Column 1-2 correspond to set of
findings provided in Semigran et al. [2015] and the corresponding transformation to the findings in
the expert system. Column 3 correspond to the ground truth label provided. Columns 4-5 provides
the top 5 diseases predicted by model trained from two configurations of the model.
needs urgent care can lead to worse outcomes than misdiagnosing a common cold. This risk in
misdiagnosis should ideally be taken into account.
Model: Functional form of g(x): Fig. 2 provides an overview of the model for computing g(x)
in eqn. 1 . The model takes as input xpos,xneg and predicts a distribution over the diagnosis. The
model has separate input streams for the demographic variables and the findings. Demographic
variables include gender and age. They impose an implicit prior over diseases that are impossible.
As examples, it is impossible for a biologically male patient to be diagnosed with ‘pregnancy’.
Similarly, its unlikely for an infant to be diagnosed with ‘dementia’. Incorporating these medically
grounded priors into the model can facilitate faster model training as they can serve as the bottle neck
over possible diagnoses. To reuse the ‘pregnancy’ example, in the early iterations of training, a male
patient with nausea and vomiting can be forced to have ‘zero’ probability mass over women-related
health issues, thereby greatly reducing the parameter search space. To model this, the embedding
layers of demographic variables are assumed to be independent, and they have their separate L-
dimensional space. The L dimensional embedding vector is used to capture the prior probabilities of
these variables to the set of L diagnoses. We assume equal prior over all diseases that are plausible
for a demographic variable. During training, the embeddings of the demographic variables are
updated to learn better representations.
We use separate embeddings for presence and absence of findings; the presence of a finding has a
distinct role to play than its absence. We use an embedding space of high dimensionality, followed
by dropout for regularization, and then averaged and projected to a fully connected layer and a log-
softmax activation function. As we can see from the model architecture (Fig. 2), the demographic
variable encodings are combined additively with the averaged embedding of the findings after a
logsoftmax transformation. This enables the bottleneck property/role that we described above.
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5 Experiments
5.1 Setup
Evaluation dataset: We evaluate the model performance using two datasets:
• Semigran: This a public dataset that was made available as part of study in Semigran et
al. Semigran et al. [2015] where over 50 online symptom checkers were evaluated. The
dataset consists of 45 standardized patient clinical vignettes, corresponding to 39 unique
diseases. We used the simplified inputs provided along with the clinical vignettes, as pre-
viously used in other studies Razzaki et al. [2018], Kannan et al. [2020].
• COVID-Assessment: In order to quantify whether COVID-19 will be included in the dif-
ferential for cases that are observed to have risk for COVID-19, we used subset of data
from the assessment tool as described in § 3.2. We construct two test sets - one that uses all
the findings in the assessment and the other that restricts to findings that are in the universe
of clinical case simulation. This ensures us that the model can infer relationships that are
not just those with the findings tabulated in tbl. 3.
Metrics: We are interested in a metric that is valuable in deployment contexts; in particular, to
aid doctors and patients in deriving the differential diagnosis so that the relevant diagnoses are
considered within a small range of false positives. For this purpose, we report top-k accuracy also
known as recall@k (k ∈ {1, 3, 5}), or sensitivity in medical literature.
top-k = recall@k =
∑T
t=1
∑j=K
j=1 [yˆ
(t)[j] = y(t)]
T
, (2)
where [a = b] is the Iverson notation that evaluates to one only if a=b or else to zero. yˆ(t)[j] is the
jth top class predicted from a model when evaluating test case t.
In order to explicitly capture the sensitivity of the model to COVID-19, we use
top-k[COVID] =
∑T
t=1
∑j=K
j=1 [yˆ
(t)[j] = COVID-19]
T
, (3)
for measuring model performance on cases from COVID-19 assessment data.
Model variants: We consider three model variants, based on the training dataset:
• Ours-BASE: This is our base model that does not have any COVID related data. The
only training data is the simulated data from only expert systems. This model is used to
compare performance of the model on publicly available test sets, and to re-establish that
expert systems can be modeled as data prior through simulation.
• Ours-BASE-COVID: This model combines the simulated data from expert systems with
the COVID assessments data. In this setting, while COVID-19 is added as an additional
label, the universe of findings F is maintained to be same as Ours-BASE.
• Ours-BASE-COVID-FULL: This is same as Ours-BASE-COVID except that all the
symptoms including travel history and exposure risks are used as inputs. The full list of
additional findings used is provided in tbl. 3
Model parameters and training details: Embedding vectors for the demographic variables are
initialized by constructing their prior distribution using expert system. For label corresponding to
COVID-19, we assume uniform prior over both demographic variables. 1024 dimensional embed-
ding vectors for the findings are initialized randomly in the range [-.05,.05]. Dropout of .7 enables
regularizing the model sufficiently to learn better representations. The model is trained with mini-
batches of size 512 using ADAM with initial learning rate of 0.01. All parameters of the model are
updated at each step of the optimization.
5.2 Approach efficacy
The goal of this first set of experiments is to re-establish that we can learn from the simulated data of
the expert systems. Table 4 compares our model to existing published results on Semigran dataset.
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Common symptoms Specific to Ours-BASE-COVID-FULL Ours-BASE Ours-BASE-COVID Ours-BASE-COVID-FULL
male
young adult (18 to 40 yrs)
fever
cough
prolonged exposure to
person with confirmed COVID-19 case
(but not close contact)
influenza (.882)
bacterial pneumonia (.073)
common cold (0.029)
acute sinusitis (0.006)
asthma (0.006)
influenza (.779)
bacterial pneumonia (.131)
COVID-19 (0.038)
common cold (0.022)
asthma (0.015)
COVID-19 (0.761)
influenza (.106)
bacterial pneumonia (0.06)
common cold (0.018)
acute sinusitis (0.012)
female
young adult (18 to 40 yrs)
chest pain
cough
dyspnea
nasal congestion
dyspnea at rest
been in Europe in the past
14 days prior to the onset of symptomshttps://www.overleaf.com/project/5ec460c385a4c1000153935a
pulmonary embolism (.372)
chronic bronchitis (.213)
asthma (0.198)
bacterial pneumonia (0.101)
influenza (0.051)
pulmonary embolism (.258)
asthma (0.216)
chronic bronchitis (.182)
bacterial pneumonia (0.151)
influenza (0.060)
COVID-19 (0.492)
pulmonary embolism (.088)
acute bronchitis (.084)
asthma (0.076)
bacterial pneumonia (0.064)
female
middle age (41 to 70 yrs)
cough
sore throat
nasal congestion
foreign travel history
None
common cold (0.843)
infectious mononucleosis (0.064)
influenza (0.029)
measles (0.018)
acute sinusitis (0.01)
COVID-19 (0.977)
common cold (0.015)
measles (0.003)
infectious mononucleosis (0.001)
influenza (.0003)
COVID-19 (0.770)
common cold (0.145)
infectious mononucleosis (0.032)
measles (0.0165)
influenza (.010)
female
middle age (41 to 70 yrs)
generalized myalgia
headache
neck stiffness
hospital personnel
West Nile fever (0.356)
bacterial meningitis (0.305)
Saint Louis encephalitis (0.249)
Lyme disease (0.069)
Rocky Mountain fever(0.005)
Saint Louis encephalitis (0.341)
West Nile fever (0.308)
bacterial meningitis (0.247)
Lyme disease (0.073)
Rocky Mountain fever(0.011)
Saint Louis encephalitis (0.398)
West Nile fever (0.320)
Lyme disease (0.078)
COVID-19 (0.053)
bacterial meningitis (0.031)
Table 6: Sample model predictions for data from COVID-19 risk assessment. Column 1 corresponds
to findings used as input in all three models. Column 2 are the additional findings used by only
Ours-BASE-COVID-FULL.
top-k Ours-BASE-COVID Ours-BASE-COVID-FULL
[COVID]
1 40% 87%
2 60% 100%
3 60% 100%
4 67% 100%
5 73% 100%
Table 7: Comparison of performance between models on the COVID assessment data.
In particular, Fraser et al. [2018] is human evaluation where twenty medical experts studied each
case in entirety (some cases include more information such as labs that are not available in patient
facing applications) and came to consensus. We can see that the top-3 accuracy is still not at 100%,
showcasing the difficulty of agreeing on diagnoses even by human experts. We also want to call out
that at the time of publication of et al. Semigran et al. [2015], the average performance of the online
symptom checkers on Semigran dataset was at 50% in top-20. In Razzaki et al. [2018], results were
provided for only 30 clinical cases. We extrapolated assuming remaining 15 cases were wrongly
diagnosed so that top-1 accuracy is at 46.6% and top-3 and 64.67%. In Kannan et al. [2020], the
training set consists of same number of diseases as the test set, while we consider a much larger
label space of diseases. We make the following observations based on tbl. 4:
• Ours-BASE performs best across all models, closing the gap with the AI expert system
that was used to simulate the dataset. This re-establishes that the approach of using ex-
pert systems as a data prior continues to hold in new settings, with different datasets and
machine learning model (§ 3 )
• Adding extra disease label (COVID-19) does not deteriorate the performance as evidenced
by Ours-BASE-COVID that has no additional findings as input. The drop in top-k accu-
racy can be attributed to the fact that there are overlapping findings that are to be reasoned.
As an example, consider first example in tbl. 5. Ours-BASE-COVID includes COVID-19
in the differential because of the overlapping findings between viral respiratory infections
and COVID-19. In contrast, in second example, with symptoms such as neck stiffness, se-
vere headache and photophobia, the model continues to maintain its prediction to be more
close to the differential diagnosis of Ours-BASE.
• Ours-BASE-COVID-FULL with additional COVID-19 findings do not change the pre-
diction accuracy as much as Ours-BASE-COVID, which is to be expected.
5.3 COVID-19 in differential diagnosis
Here, we are interested in understanding the performance of the model on COVID-
Assessment dataset. The goal is to measure the extent to which the learned models Ours-BASE-
COVID and Ours-BASE-COVID-FULL can capture COVID-19 in the differential diagnosis. Ta-
ble. 7 compares the performance. While Ours-BASE-COVID is learned by constraining input
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findings to those that are in Ours-BASE, the model is able to include COVID-19 in the differential
diagnosis in 73% of the cases. This shows that the model is able to capture overlapping findings
between COVID-19 and other diseases. When we examined cases where COVID-19 was not part of
the differential diagnosis, we found these to mainly correspond to those cases where input observa-
tions (findings) predominantly come from tbl. 3 that are related to travel and social distancing factors
which the model is unaware of. In contrast, as Ours-BASE-COVID-FULL, encodes all these find-
ings, it has COVID-19 in 100% of the assessment data (table 3 indicating ability to discriminate
COVID-19 from the rest of the diseases.
Tbl. 6 provides qualitative examples comparing the three models on the data from COVID-19 assess-
ments. These are cases with low to moderate risk of contracting COVID-19. Ours-BASE and Ours-
BASE-COVID considers only the findings in column 1 as inputs, while Ours-BASE-COVID-
FULL use the union of the first two columns as input. In the final example, as observed in Semi-
gran cases, Ours-BASE-COVID differential diagnosis is consistent with Ours-BASE. However,
once the model gets an added input of the patient being a healthcare worker, Ours-BASE-COVID-
FULL includes COVID-19 in one of its top 5 position.
6 Conclusion and Future Work
In this paper we have presented a novel approach to quickly enhance a diagnosis model that is
effective even in an extreme situation when a new previously unknown condition appears and com-
promises prior medical knowledge. Our approach combines the strengths of two very different AI
formulations: the ”old-school” traditional expert systems, with state-of-the-art deep learning mod-
els. We leverage expert systems as a way to input prior knowledge into the learned model as syn-
thetic data, and use deep learning to learn a generalizable model on the combination of old and new
data. Our model is able to capture the nuances of a new condition like COVID-19 without losing the
pre-existing medical knowledge accumulated in the expert system.
Our paper also demonstrates the efficiency of the approach even in a situation where there is little
data to train on for the new disease. In order to do so, we leverage synthetic data created by the
expert system used as a simulator, and we add real usage data of an online COVID-19 assessment
tool.
Despite the promising results and potential of our approach, it is important to acknowledge that
the model will get better as more and better data is available. In particular, in future work we do
want to include more ground truth data related to COVID-19 that incorporates all the way to the
final diagnostic test result. That being said, the flexibility of the approach means that the model can
continue to learn and to improve continuously as new data becomes available over time.
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